Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bioventus Inc.BVS · Entity 4996 | Director | June 02, 2026 | June 04, 2026 |
| Leidos Holdings, Inc.LDOS · Entity 668 | Director | February 18, 2025 | February 19, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bioventus Inc.
Report date June 02, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 138,239 |
Reported balance
After 2026-06-02 transaction · row 1
1 source rowRow 1 · 2026-06-02 · Exercise / conversion · Acquired 32,282 · Balance 138,239 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-02 · Exercise / conversion · Disposed 32,282 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2: The RSUs vested on June 2, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 25,146 |
Reported balance
After 2026-06-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-03 · Grant · Acquired 25,146 · Balance 25,146 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F3: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock.
F2: The RSUs vested on June 2, 2026.
F3: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date.
Leidos Holdings, Inc.
Report date February 18, 2025 · Filed February 19, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,985 |
Ending reported balance
After 2025-02-18 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2025-02-18 · Exercise / conversion · Acquired 4,070 · Balance 19,730 Row 2 · 2025-02-18 · Exercise / conversion · Acquired 3,345 · Balance 23,075 Row 3 · 2025-02-18 · Exercise / conversion · Acquired 2,123 · Balance 25,198 Row 4 · 2025-02-18 · Exercise / conversion · Acquired 1,769 · Balance 26,967 Row 5 · 2025-02-18 · Exercise / conversion · Acquired 2,296 · Balance 29,263 Row 6 · 2025-02-18 · Tax withholding · Disposed 8,278 · Balance 20,985 F1: Represents shares of common stock withheld by the issuer in connection with the option exercise to cover the exercise price and associated fees. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $63.08 · Expires 2025-05-10 | Direct | 0 |
Reported balance
After 2025-02-18 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-02-18 · Exercise / conversion · Disposed 4,070 · Balance 0 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $75.02 · Expires 2026-05-09 | Direct | 0 |
Reported balance
After 2025-02-18 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-02-18 · Exercise / conversion · Disposed 3,345 · Balance 0 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $103.90 · Expires 2028-05-06 | Direct | 0 |
Reported balance
After 2025-02-18 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2025-02-18 · Exercise / conversion · Disposed 2,123 · Balance 0 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $104.06 · Expires 2029-05-05 | Direct | 0 |
Reported balance
After 2025-02-18 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2025-02-18 · Exercise / conversion · Disposed 1,769 · Balance 0 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $79.45 · Expires 2030-05-04 | Direct | 0 |
Reported balance
After 2025-02-18 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2025-02-18 · Exercise / conversion · Disposed 2,296 · Balance 0 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock withheld by the issuer in connection with the option exercise to cover the exercise price and associated fees.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 12, 2017 Filed May 16, 2017 22:36 UTC | Leidos Holdings, Inc. LDOS · Entity 668 | GrantStock Option (Right to Buy) · Derivative | 4,788 | $0.00 Strike: $52.70 | $0.00 |
DisclosureSEC source: 0001225208-17-009936 · doc4.xml · derivative · entry 2 STALNECKER SUSAN M · CIK 0001221375 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,788 Underlying: Common Stock · 4,788 shares Expires 2024-05-11 F1 · derivative.exercise_date: The options shall vest and become exercisable in full on or after the earlier of (i) the first anniversary of the Grant Date, or (ii) the date that the next annual meeting of the stockholders of the Company is concluded. Read SEC document |
| May 12, 2017 Filed May 16, 2017 22:36 UTC | Leidos Holdings, Inc. LDOS · Entity 668 | GrantCommon Stock | 1,898 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-009936 · doc4.xml · nonDerivative · entry 1 STALNECKER SUSAN M · CIK 0001221375 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,417 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.